Observational Registry on the HARPOON Device (REPLICATE)
Beating Heart Mitral Valve REPair With the HARPOON™ System: ReaL World Outcomes From a multICenter observATional European Registry
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Sabrina Hundt
- Phone Number: 949-250-2500
- Email: sabrina_hundt@edwards.com
Study Contact Backup
- Name: Marieke Vijge
- Phone Number: 949-250-2500
- Email: Marieke_Vijge@edwards.com
Study Locations
-
-
Baden-Württemberg
-
Ulm, Baden-Württemberg, Germany, 89070
- Universitätsklinik Ulm
-
-
Bayern
-
Bad Neustadt, Bayern, Germany, 97616
- Rhön Klinikum Kardiochirurgie
-
Passau, Bayern, Germany, 94032
- Klinikum Passau
-
-
Niedersachsen
-
Göttingen, Niedersachsen, Germany, 37075
- Universitätsmedizin Göttingen
-
-
Nordrhein-Westfalen
-
Wuppertal, Nordrhein-Westfalen, Germany, 42283
- Helios Universitätsklinikum Wuppertal
-
-
-
-
Illes Balears
-
Palma, Illes Balears, Spain, 07010
- Hospital Son Espases
-
-
-
-
-
Bern, Switzerland, 3010
- Insel Gruppe AG, Universitätsklinik für Kardiologie, Schweizer Herz- und Gefässzentrum Bern
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subjects who are clinically suitable for treatment with the HARPOON™ System, as per the Instructions for Use (IFU), will be evaluated for inclusion in the registry.
Exclusion Criteria:
- N/A
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: HARPOON™ MVRS
Subjects who were treated with the HARPOON MVRS.
|
Repair of the chordae tendinae in the mitral valve.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Freedom From Re-operation Due to Recurrent Severe Mitral Regurgitation Through 1-year Post-implant
Time Frame: 1 year post-implant
|
Subject's freedom from re-operation due to recurrent severe mitral regurgitation through 1-year post-implant
|
1 year post-implant
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Thomas Walther, Prof Dr med, Goethe University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2019-12
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.